Clinical trialObservationalRecruiting
Spanish Series of Patients Treated With the Radionuclide Lutetium177
SEPTRALU, Spanish Series of Patients Treated With the Radionuclide Lutetium177
- Outcome
- Ongoing
- Phase
- Observational
- Status
- Recruiting
- Study type
- Observational
- Start
- 10 May 2021
- Expected end
- 31 December 2035
- Enrollment
- 5,000 participants
- Sites
- 20
- Primary outcomes
- Progression Free Survival (PFS); Overall survival (OS); Overall response rate (ORR)
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 23 December 2022
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study aims to pool the clinical experience of Spanish centers treating patients with 177Lu-DOTATATE to evaluate the efficacy, tolerance, and safety of the drug in routine clinical practice and to learn about the profiles of patients and tumors treated and the results in each type of patient and tumor.
Detailed description public domain (ClinicalTrials.gov)
Patient data will be collected from medical records after obtaining consent and retrospectively.